CARDIOVASCULAR JOURNAL OF AFRICA • Volume 34, No 2, May/June 2023 AFRICA 127 • Developing HF clinical practice guidelines for the SSA cardiovascular community that are applicable and congruent to practical HF care in SSA. Ilonze receives financial and administrative support from the National Heart, Lung, and Blood Institute (grant R25 HL105446) and the Indiana University School of Medicine. Ogunniyi receives institutional research support from Astra Zeneca, Boehringer Ingelheim and LabCorp Drug Development. References 1. Damasceno A, Mayosi BM, Sani M, Ogah OS, Mondo C, Ojji D, et al. The causes, treatment, and outcome of acute heart failure in 1006 Africans from 9 countries. Arch Intern Med 2012; 172(18): 1386–1394. 2. Sliwa K, Mayosi BM. Recent advances in the epidemiology, pathogenesis and prognosis of acute heart failure and cardiomyopathy in Africa. Heart 2013; 99(18): 1317–1322. 3. Ilonze O, Free K, Breathett K. Unequitable heart failure therapy for black, Hispanic and American-Indian patients. Card Fail Rev 2022; 8: e25. 4. Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2022; 145(18): e895–e1032. 5. Gheorghiade M, Vaduganathan M, Fonarow GC, Bonow RO. Rehospitalization for heart failure: problems and perspectives. J Am Coll Cardiol 2013; 61(4): 391–403. 6. Bozkurt B, Coats AJ, Tsutsui H, Abdelhamid M, Adamopoulos S, Albert N, et al. Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure. J Cardiac Fail 2021. 7. Ajuluchukwu JN, Raji KA. Physician-adherence to pharmacotherapy guidelines for chronic heart failure in a tertiary health facility in Lagos, Nigeria. J Hosp Admin 2014; 3(2): 8. Dokainish H, Teo K, Zhu J, Roy A, AlHabib KF, ElSayed A, et al. Heart failure in Africa, Asia, the Middle East and South America: The INTERCHF study. Int J Cardiol 2016; 204: 133–141. 9. Borlaug BA. The pathophysiology of heart failure with preserved ejection fraction. Nat Rev Cardiol 2014; 11(9): 507–515. 10. Shah KS, Xu H, Matsouaka RA, Bhatt DL, Heidenreich PA, Hernandez AF, et al. Heart failure with preserved, borderline, and reduced ejection fraction: 5-year outcomes. J Am Coll Cardiol 2017; 70(20): 2476–2486. 11. Reddy YNV, Carter RE, Obokata M, Redfield MM, Borlaug BA. A simple, evidence-based approach to help guide diagnosis of heart failure with preserved ejection fraction. Circulation 2018; 138(9): 861–870. 12. Pieske B, Tschope C, de Boer RA, Fraser AG, Anker SD, Donal E, et al. How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur Heart J 2019; 40(40): 3297–3317. 13. Gronda E, Vanoli E, Iacoviello M. The PARAGON-HF trial: the sacubitril/valsartan in heart failure with preserved ejection fraction. Eur Heart J 2020; 22(Suppl L): L77–L81. 14. Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 2014; 370(15): 1383–1392. 15. Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Bohm M, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 2021; 385(16): 1451–1461. 16. Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF, et al. Dapagliflozin in Heart failure with mildly reduced or preserved ejection fraction. N Engl J Med 2022; 387(12): 1089–1098. 17. Karaye KM, Sa’idu H, Balarabe SA, Ishaq NA, Adamu UG, Mohammed IY, et al. Clinical features and outcomes of peripartum cardiomyopathy in Nigeria. J Am Coll Cardiol 2020; 76(20): 2352–2364. 18. Maron BJ, Rowin EJ, Maron MS. Global burden of hypertrophic cardiomyopathy. J Am Coll Cardiol Heart Fail 2018; 6(5): 376–378. 19. Marian AJ, Braunwald E. Hypertrophic cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy. Circ Res 2017; 121(7): 749–770. 20. Olivotto I, Oreziak A, Barriales-Villa R, Abraham TP, Masri A, GarciaPavia P, et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2020; 396(10253): 759–769. 21. Desai MY, Owens A, Geske JB, Wolski K, Naidu SS, Smedira NG, et al. Myosin inhibition in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy. J Am Coll Cardiol. 2022; 80(2): 95–108. 22. Maron BJ, Desai MY, Nishimura RA, Spirito P, Rakowski H, Towbin JA, et al. Diagnosis and evaluation of hypertrophic cardiomyopathy: JACC state-of-the-art review. J Am Coll Cardiol 2022; 79(4): 372–389. 23. Dungu JN, Anderson LJ, Whelan CJ, Hawkins PN. Cardiac transthyretin amyloidosis. Heart 2012; 98(21): 1546–1554. 24. Connors LH, Prokaeva T, Lim A, Theberge R, Falk RH, Doros G, et al. Cardiac amyloidosis in African Americans: comparison of clinical and laboratory features of transthyretin V122I amyloidosis and immunoglobulin light chain amyloidosis. Am Heart J 2009; 158(4): 607–614. 25. Jacobson DR, Alexander AA, Tagoe C, Buxbaum JN. Prevalence of the amyloidogenic transthyretin (TTR) V122I allele in 14 333 AfricanAmericans. Amyloid 2015; 22(3): 171–174. 26. Ruberg FL, Maurer MS, Judge DP, Zeldenrust S, Skinner M, Kim AY, et al. Prospective evaluation of the morbidity and mortality of wildtype and V122I mutant transthyretin amyloid cardiomyopathy: the Transthyretin Amyloidosis Cardiac Study (TRACS). Am Heart J 2012; 164(2): 222–228. 27. Van den Berg MP, Mulder BA, Klaassen SHC, Maass AH, van Veldhuisen DJ, van der Meer P, et al. Heart failure with preserved ejection fraction, atrial fibrillation, and the role of senile amyloidosis. Eur Heart J 2019; 40(16): 1287–1293. 28. King P, Kates AM. Management of cardiac symptoms in amyloidosis. Am J Med 2022; 135(Suppl 1): S9–S12. 29. Zegri-Reiriz I, de Haro-Del Moral FJ, Dominguez F, Salas C, de la Cuadra P, Plaza A, et al. Prevalence of cardiac amyloidosis in patients with carpal tunnel syndrome. J Cardiovasc Transl Res 2019; 12(6): 507–513. 30. Dungu J, Sattianayagam PT, Whelan CJ, Gibbs SD, Pinney JH, Banypersad SM, et al. The electrocardiographic features associated with cardiac amyloidosis of variant transthyretin isoleucine 122 type in AfroCaribbean patients. Am Heart J 2012; 164(1): 72–79. 31. Castano A, Haq M, Narotsky DL, Goldsmith J, Weinberg RL, Morgenstern R, et al. Multicenter study of planar technetium 99m pyrophosphate cardiac imaging: predicting survival for patients with ATTR cardiac amyloidosis. J AmMed Assoc Cardiol 2016; 1(8): 880–889. 32. Gertz M, Adams D, Ando Y, Beirao JM, Bokhari S, Coelho T, et al. Avoiding misdiagnosis: expert consensus recommendations for the suspicion and diagnosis of transthyretin amyloidosis for the general
RkJQdWJsaXNoZXIy NDIzNzc=